by John Conrad | Oct 8, 2024 | Member News
Astellas Pharma Inc. and AviadoBio Ltd. have announced an exclusive option and license agreement for AVB-101, a promising gene therapy currently in Phase 1/2 clinical trials. This collaboration marks a significant step forward in addressing the urgent need for...
by John Conrad | Oct 3, 2024 | Member News
Eli Lilly and Company, a leading pharmaceutical giant, has announced plans to invest $4.5 billion in a groundbreaking new facility aimed at revolutionizing drug production and accelerating the development of medicines for clinical trials. The announcement comes as...
by John Conrad | Oct 2, 2024 | Member News
In a significant development for patients with Primary Biliary Cholangitis (PBC), COUR Pharmaceuticals has announced encouraging results from its Phase 2a clinical trial of CNP-104, a potential game-changer in the treatment of this chronic liver disease. What is PBC?...
by John Conrad | Oct 1, 2024 | Member News
Endotronix, an Edwards Lifesciences company, has announced groundbreaking one-year clinical results for their Cordella Pulmonary Artery (PA) Sensor System, marking a significant advancement in heart failure management. The data, presented at the Heart Failure Society...
by John Conrad | Sep 26, 2024 | Member News
ARCH Venture Partners, the Chicago-based venture capital firm known for its bold bets in biotechnology, has once again demonstrated its commitment to driving healthcare innovation. The firm announced on September 26, 2024, that it has raised $3 billion for its...
by John Conrad | Sep 25, 2024 | NewsBrief
PCI Pharma Services is set to significantly expand its presence in Rockford, Illinois, as part of a broader $365 million investment across its U.S. and European operations. The contract development and manufacturing organization (CDMO) announced on Tuesday, September...
